ReviewCNS drugs2013
Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine.
Review in CNS drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Dihydroergotamine (DHE) - Then and Now: A Narrative Review.Headache · 2020Pooled it
- Trial
- STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (PODHeadache · 2021Trial
- Trial
- Tolerability of repetitive dihydroergotamine infusions paired with an adjustment in preventive treatment strategy in chronic headache disorders in children and youth.The journal of headache and pain · 2025Article
- Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea-A narrative review.Headache · 2025Review
- Role of Phytocompounds for Effective Management of Migraine: Current and Future Prospectives.Central nervous system agents in medicinal chemistry · 2025Review
- The Gut-brain Connection and Episodic Migraine: an Update.Current pain and headache reports · 2023Review
- Medication Overuse Headache: an Updated Review and Clinical Recommendations on Management.Current neurology and neuroscience reports · 2023Review
- New characterization of dihydroergotamine receptor pharmacology in the context of migraine: utilization of a β-arrestin recruitment assay.Frontiers in neurology · 2023Article
- Management of a patient with unintended intravenous dihydroergotamine infusion extravasation causing brachial artery vasospasm.Proceedings (Baylor University. Medical Center) · 2023Article
- Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action.Journal of aerosol medicine and pulmonary drug delivery · 2022Review
- Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations.Journal of pain research · 2020Review
- The role of αThe journal of headache and pain · 2017Article
- Cutaneous Adverse Effects of Neurologic Medications.CNS drugs · 2016Review
- Two genomes are better than one: history, genetics, and biotechnological applications of fungal heterokaryons.Fungal biology and biotechnology · 2016Review
- The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination: an update.Translational respiratory medicine · 2014Review
- Orofacial pain management: current perspectives.Journal of pain research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dihydroergotamine (DHE) was first used to treat migraine in 1945 and is currently included among migraine-specific treatments for moderate-severe migraine. DHE may be administered through several routes of delivery, with efficacy and tolerability varying among formulations. We review DHE formulation approaches for the acute treatment of migraine, reviewing pharmacokinetics/dynamics and comparing clinical response among various formulations. Pharmacokinetic properties vary among DHE formulations, with peak concentration occurring in 6 min with intravenous, 34 min with intramuscular, 56 min with intranasal, 12 min with oral inhalation and 75 min with oral administration. DHE is a potent agonist at serotonin 5-HT1B and 5-HT1D receptors. Adverse effects due to binding to select adrenergic and dopaminergic receptors are significantly less with orally inhaled than intravenous DHE when comparing therapeutically effective doses. Among parenteral formulations (including subcutaneous, intramuscular, intravenous and nasal spray), efficacy is superior with injectable dosing. Nasal spray DHE is generally more effective than placebo, but less effective than sumatriptan. Orally inhaled DHE is likewise more effective than placebo, but there are no head-to-head comparisons with triptans available for review. Adverse effects, particularly nausea, may limit use of parenteral DHE. Nausea is generally less frequent with non-injectable dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.